Leo Leng has 17-year healthcare industry experience, including 14 years of investment and M&A practice in pharmaceutical industry. Leo once worked in Simcere Pharmaceutical Group Limited and Beijing sinobioway Group Co., Ltd. Leo joined Legend Star in 2013 and was promoted to be partner and an Investment Committee member in 2017. Leo has been committed to investing in healthcare, especially new biological medicine, molecular diagnosis and gene sequencing, tumor immunology and cell therapy, medical-grade sensors, and data collection terminals. Leo has made dozens of investments in those sectors including Axonics (NASDAQ: AXNX), Burning Rock (NASDAQ: BNR), Keymed Biosciences (2162.HK), Ribo, Coyote Bioscience, Cothera, HiFiBio, Qihan Biotech, Lupeng Pharmaceutical, Carmine, Reetoo, Genhouse Bio and Syngene Bio. Leo was awarded as one of the top ten Angel investors of Zhongguancun in 2016 and the 2019 Beijing High-end Leading Talent. Leo received a Master’s Degree from the School of Economics and Management, Tsinghua University, and a Bachelor’s Degree from the School of Life Sciences, Xiamen University.